Jubilant Pharma UK Limited
Balance Sheet as at 31 March 2026
(All amounts in GBP, unless otherwise stated)

	Notes	As at 31 March 2026	As at 31 March 2025
ASSETS			
Non-current assets			
Property, plant and equipment	3	1,448	2,528
Financial assets			
i. Loans	4	1,558	1,558
Total non-current assets		**3,006**	**4,086**
Current assets			
Inventories	5	9,26,352	35,22,957
Financial assets			
i. Trade receivables	6	22,25,532	22,94,095
ii. Cash and cash equivalents	7	1,07,944	2,39,014
iii. Other financial assets	8	962	-
Other current assets	9	9,555	6,439
Total current assets		**32,70,345**	**60,62,505**
Total assets		**32,73,351**	**60,66,591**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	5,000	5,000
Other equity		5,53,389	5,05,748
Total equity		**5,58,389**	**5,10,748**
Liabilities			
Non-current liabilities			
Provisions	12	8,197	8,197
Deferred tax liabilities (net)	10	362	632
Total non-current liabilities		**8,559**	**8,829**
Current liabilities			
Financial liabilities			
i. Trade payables	13	23,60,430	51,31,509
ii. Other financial liabilities	14	3,492	4,656
Other current liabilities	15	3,12,949	2,77,316
Current tax liabilities (net)	16	29,532	1,33,533
Total current liabilities		**27,06,403**	**55,47,014**
Total liabilities		**27,14,962**	**55,55,843**
Total equity and liabilities		**32,73,351**	**60,66,591**

For Jubilant Pharma UK Limited

Dr. Jaidev Sanjeev Rajpal
(Director)
Date: 19 May 2026

Jubilant Pharma UK Limited
Statement of Profit and Loss for the year ended 31 March 2026
(All amounts in GBP, unless otherwise stated)

	Notes	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue from operations	17	77,48,160	91,41,652
Other income	18	962	-
Total income		**77,49,122**	**91,41,652**
Expenses			
Cost of materials consumed	19	2,63,059	1,64,981
Purchases of stock-in-trade	20	31,04,513	62,73,150
Changes in inventories of finished goods, stock-in-trade and work-in-progress	21	25,96,605	8,31,336
Employee benefits expense	22	1,92,920	1,85,573
Depreciation and amortisation expense	23	1,079	857
Other expenses	24	14,98,890	11,38,114
Total expenses		**76,57,066**	**85,94,011**
Profit before exceptional items and tax		**92,056**	**5,47,641**
Exceptional items			
Profit before tax		**92,056**	**5,47,641**
Tax expense			
- Current tax		44,685	1,45,157
- Deferred tax (credit)/charge		(270)	24,105
Total tax expense		**44,415**	**1,69,262**
Profit for the year		**47,641**	**3,78,379**
Other comprehensive income for the year, net of tax		**-**	**-**
Total comprehensive income for the year		**47,641**	**3,78,379**

For Jubilant Pharma UK Limited

Dr. Jaidev Sanjeev Rajpal
(Director)
Date: 19 May 2026

Jubilant Pharma UK Limited
Statement of Cash Flows for the year ended 31 March 2026
(All amounts in GBP, unless otherwise stated)

	As at 31 March 2026	As at 31 March 2025
A. Cash flow from operating activities		
Net profit before tax	92,056	5,47,641
Adjustments:		
Depreciation and amortisation expense	1,079	857
Unrealised foreign exchange (gain)	(321)	-
	759	**857**
Operating cash flow before working capital changes	**92,814**	**5,48,498**
Decrease/ (Increase) in trade receivables, loans, other financial assets and other assets	64,485	(1,67,160)
Decrease in inventories	25,96,605	8,31,336
Decrease in trade payables, other financial liabilities, other liabilities and provisions	(27,36,289)	(11,03,321)
Cash generated from operations	**17,615**	**1,09,353**
Income tax paid (net of refund)	(1,48,686)	(11,624)
Net cash (used in)/ generated from operating activities	**(1,31,070)**	**97,729**
B. Cash flow from investing activities		
Purchase of property, plant and equipment and other intangible assets	-	(1,554)
Net cash used in investing activities	**-**	**(1,554)**
Net (decrease)/ increase in cash and cash equivalents (A+B)	**(1,31,070)**	**96,175**
Cash and cash equivalents at the beginning of year	2,39,014	1,42,839
Cash and cash equivalents at the end of the year	**1,07,944**	**2,39,014**

For Jubilant Pharma UK Limited

Dr. Jaidev Sanjeev Rajpal
(Director)
Date: 19 May 2026

Jubilant Pharma UK Limited
Statement of Changes in Equity for the year ended 31 March 2026
(All amounts in GBP, unless otherwise stated)

A. Equity share capital	Amount
Balance as at 1 April 2024	**5,000**
Changes in equity share capital during the year	-
Balance as at 31 March 2025	**5,000**
Changes in equity share capital during the year	-
Balance as at 31 March 2026	**5,000**

B. Other equity

	Reserves and surplus	Total
	Retained earnings	
Balance as at 31 March 2025	**1,27,369**	**1,27,369**
Profit for the year	3,78,379	3,78,379
Other comprehensive income/(loss)	-	-
Total comprehensive income for the year	**3,78,379**	**3,78,379**
Balance as at 31 March 2026	**5,05,748**	**5,05,748**
Profit for the year	47,641	47,641
Other comprehensive income/(loss)	-	-
Total comprehensive income for the year	**47,641**	**47,641**
Balance as at 31 March 2026	**5,53,389**	**5,53,389**

For Jubilant Pharma UK Limited

Dr. Jaidev Sanjeev Rajpal
(Director)
Date: 19 May 2026

Note 1: Corporate information

Jubilant Pharma UK Limited ("the Company") is private company limited by share capital incorporated in England and Wales ("UK"). The Company is a wholly owned subsidiary of Jubilant Pharma Limited ("the holding company") a company registered in Singapore whose ultimate parent company is Jubilant Pharmova Limited, a company incorporated in India. The company is engaged in wholesale of pharmaceutical goods.

Note 2. Material accounting policies

This note provides a list of the significant accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

(a) Basis of preparation

(i) Statement of compliance

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

(ii) Historical cost convention

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is Great British Pound ("GBP"). These financial statements are presented in GBP.

(c) Current versus non-current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.
An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current-non-current classification of assets and liabilities.

Note 3: Property, plant and equipment and capital work-in-progress

Description	Computers	Total
Gross carrying amount as at 1 April 2024	**3,100**	**3,100**
Additions	**1,554**	**1,554**
Deductions	-	-
Gross carrying amount as at 31 March 2025	**4,654**	**4,654**
Accumulated depreciation as at 1 April 2024	**1,270**	**1,270**
Depreciation charge for the year	857	857
Accumulated depreciation as at 31 March 2025	**2,127**	**2,127**
Net carrying amount as at 31 March 2025	**2,528**	**2,528**

Description	Computers	Total
Gross carrying amount as at 1 April 2025	**4,654**	**4,654**
Additions	-	-
Deductions	-	-
Gross carrying amount as at 31 March 2026	**4,654**	**4,654**
Accumulated depreciation as at 1 April 2025	**2,127**	**2,127**
Depreciation charge for the year	1,079	1,079
Accumulated depreciation as at 31 March 2026	**3,206**	**3,206**
Net carrying amount as at 31 March 2026	**1,448**	**1,448**

Note 4: Non-current loans

	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Security deposits	1,558	1,558
Total non-current loans	**1,558**	**1,558**

Note 5: Inventories

	As at 31 March 2026	As at 31 March 2025
Stock-in-trade	9,26,352	35,22,957
Total inventories	**9,26,352**	**35,22,957**

Note 6: Trade receivables

	As at 31 March 2026	As at 31 March 2025
Unsecured and current		
Trade receivables - considered good	22,25,532	21,83,702
Receivables from related parties	-	1,10,393
Total trade receivables	**22,25,532**	**22,94,095**

Note 7: Cash and cash equivalents

	As at 31 March 2026	As at 31 March 2025
Balances with banks		
- in current accounts	1,07,944	2,39,014
Total cash and cash equivalents	**1,07,944**	**2,39,014**

Note 8: Other current financial assets

	As at 31 March 2026	As at 31 March 2025
Recoverable from related parties	962	-
Total other current financial assets	**962**	**-**

Note 9: Other current assets

	As at 31 March 2026	As at 31 March 2025
Prepaid expenses	6,477	6,439
Advance for supply of goods and services	3,078	-
Total other current assets	**9,555**	**6,439**

Note 10: Deferred tax (liabilities)

	As at 31 March 2026	As at 31 March 2025
Deferred tax assets		
Property, plant and equipment	(362)	(632)
Deferred tax assets (net)	**(362)**	**(632)**

Note 11: Equity share capital

	As at 31 March 2026	As at 31 March 2025
Paid up share capital		
5000 Common stock of GBP 1 each	5,000	5,000
	5,000	**5,000**

Movement in equity share capital	No. of shares	Amount
As at 1 April 2024	5,000	5,000
Additions during the year	-	-
As at 31 March 2025	5,000	5,000
Additions during the year	-	-
As at 31 March 2026	5,000	5,000

Terms and rights attached to equity shares

The Company has only one class of Common stock referred to herein as equity shares. Each holder of common stock is entitled to one vote per common stock. In the event of liquidation of the Company, the stockholders shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of common stock of equity shares held by the stockholders.

Details of shareholders holding more than 5% shares in the Company:

	As at 31 March 2026		As at 31 March 2025	
	No. of shares	% holding	No. of shares	% holding
Jubilant Pharma Limited - the holding company Common stock of GBP 1 each	5,000	100.00%	5,000	100.00%

Note 12: Non-current provisions

	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Provision for employee benefits	8,197	8,197
Total provisions	**8,197**	**8,197**

Note 13: Trade payables

	As at 31 March 2026	As at 31 March 2025
Current		
Dues to relates parties	18,98,456	45,84,426
Dues to others	4,61,974	5,47,083
Total trade payables	**23,60,430**	**51,31,509**

Note 14: Other current financial liabilities

	As at 31 March 2026	As at 31 March 2025
Employee benefits payable	3,492	4,656
Total other current financial liabilities	**3,492**	**4,656**

Note 15: Other current liabilities

	As at 31 March 2026	As at 31 March 2025
Statutory dues payables	3,12,949	2,77,316
Total other current liabilities	**3,12,949**	**2,77,316**

Note 16: Current tax liabilities (Net)

	As at 31 March 2026	As at 31 March 2025
Provision for income tax & wealth tax	29,532	1,33,533
Total current tax liabilities (Net)	**29,532**	**1,33,533**

Note 17: Revenue from operations

	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of products	77,48,160	91,41,652
Total revenue from operations	**77,48,160**	**91,41,652**

Note 18: Other income

	For the year ended 31 March 2026	For the year ended 31 March 2025
Other non-operating income	962	-
Total other income	**962**	**-**

Note 19: Cost of materials consumed

	For the year ended 31 March 2026	For the year ended 31 March 2025
Raw materials consumed	2,63,059	1,64,981
Total cost of materials consumed	**2,63,059**	**1,64,981**

Note 20: Purchase of stock-in-trade

	For the year ended 31 March 2026	For the year ended 31 March 2025
Purchase of stock-in-trade	31,05,299	62,73,150
Total purchase of stock-in-trade	**31,05,299**	**62,73,150**

Note 21: Changes in inventories of finished goods, stock-in-trade and work-in-progress

	For the year ended 31 March 2026	For the year ended 31 March 2025
Opening balance		
Stock-in-trade	35,22,957	43,54,294
Total opening balance	**35,22,957**	**43,54,294**
Closing balance		
Stock-in-trade	9,26,352	35,22,957
Total closing balance	**9,26,352**	**35,22,957**
Total changes in inventories of finished goods, stock-in-trade and work-in-progress	**(25,96,605)**	**(8,31,336)**

Note 22: Employee benefits expense

	For the year ended 31 March 2026	For the year ended 31 March 2025
Salaries, wages, bonus, gratuity and allowances	1,67,017	1,63,734
Contribution to provident fund, superannuation and other funds	25,725	21,839
Staff welfare expenses	178	-
Total employee benefits expense	**1,92,920**	**1,85,573**

Note 23: Depreciation and amortisation expense

	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation of property, plant and equipment	1,079	857
Total depreciation and amortisation expense	**1,079**	**857**

Note 24: Other expenses

	For the year ended 31 March 2026	For the year ended 31 March 2025
Power and fuel	132	119
Consumption of stores and spares and packing materials	2,80,641	2,17,029
Rental charges	9,857	9,176
Rates and taxes	76,197	20,566
Insurance	19,896	18,179
Advertisement, publicity and sales promotion	1,26,150	2,129
Travel and conveyance	9,360	8,633
Printing and stationery	44	127
Donation	25,000	-
Payments to statutory auditors	9,250	11,550
Legal and professional fees	4,55,028	4,78,483
Freight and forwarding	38,034	1,510
Subscription	16,672	16,173
Bank charges	1,665	2,279
Claims and other selling expenses	4,30,836	3,49,936
Net foreign exchange loss	128	2,225
Total other expenses	**14,98,890**	**11,38,114**